Cara Therapeutics (CARA) Reports In-Line Q3 EPS
Tweet
Share
E-mailGet Alerts CARA Hot Sheet
Join SI Premium – FREE
Cara Therapeutics (NASDAQ: CARA) reported Q3 EPS of ($0.52), in-line with the analyst estimate of ($0.52). Revenue for the quarter came in at $4.87 million versus the consensus estimate of $9.95 million.
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CarGurus (CARG) Tops Q2 EPS by 5c ; Offers Guidance
- Netgear, Inc. (NTGR) Tops Q2 EPS by 15c
- Valhi, Inc. (VHI) Misses Q2 EPS by 18c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
